Serina Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $130.0K | $56.0K | $3.2M | $34.0K | $144.0K | $361.0K | $1.7M | $1.4M |
| Cost of Revenue | — | — | $40.0K | $13.0K | $19.0K | $26.0K | $244.0K | $364.0K |
| Gross Profit | — | — | $102.0K | $21.0K | $125.0K | $335.0K | $1.5M | $1.0M |
| Gross Margin | — | — | 3.2% | 61.8% | 86.8% | 92.8% | 85.9% | 73.9% |
| Operating Expenses | ||||||||
| Research & Development | $13.2M | $7.5M | $2.4M | $1.0M | $1.5M | $3.7M | $5.9M | $5.8M |
| SG&A Expense | $11.0M | $9.6M | $3.9M | $6.0M | $6.7M | $6.7M | $8.1M | $5.6M |
| Operating Income | $-24.0M | $-17.0M | $-3.1M | $-7.0M | $-7.9M | $-10.1M | $-12.6M | $-11.2M |
| Operating Margin | -18,478.5% | -30,442.9% | -99.2% | -20,514.7% | -5,509.0% | -2,797.8% | -726.8% | -805.5% |
| Interest Expense | — | — | $4.9M | $3.3M | $1.1M | — | — | — |
| Pretax Income | $-19.2M | $-11.2M | $5.3M | $10.5M | $8.7M | $-11.1M | $-12.2M | $-7.7M |
| Income Tax Expense | $18.0K | $0 | $0 | — | — | $-150.0K | $148.0K | — |
| Net Income | $-19.2M | $-11.1M | $5.3M | $-10.5M | $-8.7M | $-10.9M | $-12.2M | $-7.5M |
| Net Margin | -14,755.4% | -19,894.6% | 167.1% | -30,770.6% | -6,024.3% | -3,009.7% | -703.4% | -537.4% |
| EPS (Basic) | $-1.91 | $-1.51 | $2.36 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS (Diluted) | $-1.91 | $-1.51 | $0.73 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | 10.2M | 7.4M | 2.2M | 258.52B | 258.12B | 256.79B | 256.50B | 244.11B |
| Shares Outstanding (Diluted) | 10.2M | 7.4M | 7.4M | 7.4M | 258.12B | 256.79B | 256.50B | 244.11B |
| Dividends Per Share | — | — | — | — | — | — | — | — |